ABC | Volume 114, Nº5, May 2020

Review Article Askin et al. COVID-19 and cardiovascular diseases Arq Bras Cardiol. 2020; 114(5):817-822 This is an open-access article distributed under the terms of the Creative Commons Attribution License 39. Brilinta (Ticagrelor) - Prescribing information. Wilmington, DE: AstraZeneca LP; 2011 40. Brilinta (ticagrelor). Product monograph. Mississauga, Ontario, Canada: AstraZeneca Canada Inc.,:2011. 41. Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther. 2019;105(1):219-28. 42. Marsousi N, Daali Y, Fontana P, Reny JL, Ancrenaz-Sirot V, Calmy A, et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel activemetabolites. Clin Pharmacokinet. 2018;57(10):1347-54. 43. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International expert consensus on switching platelet P2Y12 receptor- inhibiting therapies. Circulation. 2017;136(20):1955-75. 44. Kengreal [package insert]. Cary, NC: Chiesi USA, INC; 2015. 45. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-303. 46. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavíirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. 47. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. 48. TonnesmannE,KandolfR,LewalterT.Chloroquinecardiomyopathy-areview of the literature. Immunopharmacol Immunotoxicol. 2013;35(3):434-42. 49. Driggin E, MadhavanMV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020 Mar 18:pii:S0735-1097(20)34637-4. 50. Liu Y, Yang Y, Zhang C, Huang F,Wang F, Yuan J,et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364-74. 51. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020 Mar 18;pii:taaa041. 52. Chen C, Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin XueGuan Bing Za Zhi. 2020;48(0):E008. 53. Fang L, Karakiulakis G, RothM. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. 54. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients fromWuhan, China. Intensive Care Med. 2020 Mar 3. [Epub ahead of print]. 55. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 Mar 11. [Epub ahead of print]. 56. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020 May;177:104762. 57. GuanWJ, LiangWH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020 Mar 26;pii:2000547. 58. Inciardi RM, Lupi L, Zaccone G, Italia L, RaffoM, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. [Epub ahead of print]. 59. GuoT,FanY,ChenM,WuX,ZhangL,HeT,etal.Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. [Epub ahead of print]. 60. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25. [Epub ahead of print]. 61. Chen X, HuW, Ling J, Mo P, Zhang Y, JiangQ, et al. Hypertension and diabetes delay the viral clearance in COVID-19 patients. medRxiv. 2020Mar 24. 62. Tignanelli CJ, IngrahamNE, Sparks MA, Reilkoff R, Bezdicek T, Benson B, et al. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020 Mar 26. [Epub ahead of print]. 822